{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T17:19:31.640337+00:00","company":{"ticker":"BMRA","cik":73290,"company_name":"BIOMERICA INC"},"pagination":{"limit":100,"returned":30,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Craig-Hallum Capital Group LLC","detail":"underwriting","count":1,"first_seen":"2023-03-07T23:59:59+00:00","last_seen":"2023-03-07T23:59:59+00:00","evidence_fact_ids":[173601]},{"display_name":"EF Hutton LLC and R.F. Lafferty & Co., Inc.","detail":"atm_program","count":1,"first_seen":"2024-05-10T23:59:59+00:00","last_seen":"2024-05-10T23:59:59+00:00","evidence_fact_ids":[48460]}],"lender":[{"display_name":"Buyers affiliated with Zackary Irani, the Company’s Chief Executive Officer","detail":"loan","count":1,"first_seen":"2026-06-04T20:45:41+00:00","last_seen":"2026-06-04T20:45:41+00:00","evidence_fact_ids":[67569]}]},"facts":[{"fact_type":"debt_financing","fact_key":"b9bcac5cde8e208c7630a7bf6f0b781d2538e8db","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2026-06-04T20:45:41+00:00","payload":{"counterparty":"Buyers affiliated with Zackary Irani, the Company’s Chief Executive Officer","effective_date":"2026-05-29","event":"incurrence","instrument_type":"loan","interest_rate_text":"8% per annum","item_codes_triggered":["2.03"],"maturity_text":"12 months from the Effective Date","principal_text":"$500,000"},"claim":"BIOMERICA INC incurred loan of $500,000 with Buyers affiliated with Zackary Irani, the Company’s Chief Executive Officer at 8% per annum maturing 12 months from the Effective Date.","evidence_excerpt":"the Buyers delivered the Purchase Price in exchange for a secured promissory term note (the “Note”) in the principal amount of $500,000. The Note bears interest at a rate of 8% per annum (the “Stated Interest Rate”) and matures 12 months from the Effective Date","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-027290","anchor_url":"https://secwatch.observer/filing/0001493152-26-027290#claim-b9bcac5cde8e208c7630a7bf6f0b781d2538e8db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315226027290/0001493152-26-027290-index.htm"},{"fact_type":"executive_change","fact_key":"09bc2fc797","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-04","interim":false,"role":"Director and Audit Committee Chair","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric Chin was appointed as Director and Audit Committee Chair at BIOMERICA INC.","evidence_excerpt":"On the same date, the Board appointed Mr. Eric Chin to serve as an independent member of the Board, effective immediately","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-013942","anchor_url":"https://secwatch.observer/filing/0001641172-25-013942#claim-09bc2fc797","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000164117225013942/0001641172-25-013942-index.htm"},{"fact_type":"executive_change","fact_key":"a6ca26070b","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-04","interim":false,"role":"Director","role_category":"director","successor_name":"Eric Chin","successor_named":true},"claim":"Cathy Coste resigned as Director at BIOMERICA INC.","evidence_excerpt":"Effective June 4, 2025, Ms. Cathy Coste stepped down as a member of the Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001641172-25-013942","anchor_url":"https://secwatch.observer/filing/0001641172-25-013942#claim-a6ca26070b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000164117225013942/0001641172-25-013942-index.htm"},{"fact_type":"governance_change","fact_key":"e6c0a3d51b7556918f40cfde90cd0c88a298ff7c","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2025-04-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-04-15","item_codes_triggered":["5.03"],"summary_text":"Amendment to Certificate of Incorporation to effect a 1-for-8 reverse stock split"},"claim":"BIOMERICA INC: Amendment to Certificate of Incorporation to effect a 1-for-8 reverse stock split (effective 2025-04-15).","evidence_excerpt":"On April 15, 2025, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, to be effective at 12:01 a.m. Eastern Time on April 21, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-004976","anchor_url":"https://secwatch.observer/filing/0001641172-25-004976#claim-e6c0a3d51b7556918f40cfde90cd0c88a298ff7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000164117225004976/0001641172-25-004976-index.htm"},{"fact_type":"executive_change","fact_key":"ba60fdd557","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2024-06-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-26","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Jack Kenny resigned as Chairman of the Board at BIOMERICA INC.","evidence_excerpt":"On June 26, 2024, Mr. Jack Kenny notified Biomerica, Inc. (the \"Company\") of his resignation as a member of the board of directors of the Company (the \"Board\") and all committees thereof, and as the Company’s Chairman of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-025656","anchor_url":"https://secwatch.observer/filing/0001493152-24-025656#claim-ba60fdd557","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315224025656/0001493152-24-025656-index.htm"},{"fact_type":"material_agreement","fact_key":"54309b36e2f04445ea202411c2069c506097fa4f","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"At Market Issuance Sales Agreement","agreement_type":"atm_program","counterparty":"EF Hutton LLC and R.F. Lafferty & Co., Inc.","effective_date":"2024-05-10","item_codes_triggered":["1.01"],"value_text":"$5,500,000"},"claim":"BIOMERICA INC entered into At Market Issuance Sales Agreement with EF Hutton LLC and R.F. Lafferty & Co., Inc. valued at $5,500,000 (effective 2024-05-10).","evidence_excerpt":"On May 10, 2024, Biomerica, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with EF Hutton LLC and R.F. Lafferty & Co., Inc. (each individually, a “Sales Agent” and together, the “Sales Agents”), pursuant to which the Company may offer and sell from time to time up to an aggregate of $5,500,000 of shares of the Company’s common stock","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018697","anchor_url":"https://secwatch.observer/filing/0001493152-24-018697#claim-54309b36e2f04445ea202411c2069c506097fa4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/0001493152-24-018697-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"e1e69623663c9f1df953d877daa9a4225d0adfbc","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-05-07","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(a)(2)","reported_value":null,"rule_numbers":["5550(a)(2)"],"rules_cited_in_text":true},"claim":"BIOMERICA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 7, 2024, Biomerica, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that the closing bid price for the Company’s common stock had been below $1.00\nper share for the previous 32 consecutive business days and that the Company is no longer in compliance with the minimum bid price requirement\nunder Nasdaq Listing Rule 5550(a)(2) (the “Rule”). The\nNotice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market. The\nNotice indicates the Company will have 180 calenda","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018697","anchor_url":"https://secwatch.observer/filing/0001493152-24-018697#claim-e1e69623663c9f1df953d877daa9a4225d0adfbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315224018697/0001493152-24-018697-index.htm"},{"fact_type":"shareholder_vote","fact_key":"828982ff31f4bbfddffa3c226a8b5896caf4da31","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-12-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-07","outcome":"passed","proposal_text":"Ratification and approval of an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"4,509,073","subject":null,"votes_abstain":"6,133","votes_against":"152,436","votes_for":"5,906,540","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification and approval of an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum at the 2023-12-07 meeting.","evidence_excerpt":"Proposal No. 5 : The shareholders ratified and approved an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044431","anchor_url":"https://secwatch.observer/filing/0001493152-23-044431#claim-828982ff31f4bbfddffa3c226a8b5896caf4da31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223044431/0001493152-23-044431-index.htm"},{"fact_type":"shareholder_vote","fact_key":"395bc6d2cbbd4c6e9539d1695692286f9add760d","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-12-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-07","outcome":"passed","proposal_text":"Ratification and approval of the 2023 Stock Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"4,509,073","subject":null,"votes_abstain":"462,867","votes_against":"87,185","votes_for":"5,515,057","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification and approval of the 2023 Stock Incentive Plan at the 2023-12-07 meeting.","evidence_excerpt":"Proposal No. 4 : The shareholders voted to ratify and approve the 2023 Stock Incentive Plan.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044431","anchor_url":"https://secwatch.observer/filing/0001493152-23-044431#claim-395bc6d2cbbd4c6e9539d1695692286f9add760d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223044431/0001493152-23-044431-index.htm"},{"fact_type":"shareholder_vote","fact_key":"970fa73b3ad3c5fc7f3697b8466d9374380c6628","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-12-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-07","outcome":"passed","proposal_text":"Ratification of the appointment of Haskell & White LLP as the Company’s independent public accounting firm for the fiscal year ending May 31, 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"6,381","votes_against":"21,702","votes_for":"10,546,099","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification of the appointment of Haskell & White LLP as the Company’s independent public accounting firm for the fiscal year ending May 31, 2024 at the 2023-12-07 meeting.","evidence_excerpt":"Proposal No. 3 : The Company’s stockholders ratified the appointment of Haskell & White LLP as the Company’s independent public accounting firm for the fiscal year ending May 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044431","anchor_url":"https://secwatch.observer/filing/0001493152-23-044431#claim-970fa73b3ad3c5fc7f3697b8466d9374380c6628","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223044431/0001493152-23-044431-index.htm"},{"fact_type":"shareholder_vote","fact_key":"653a70d1804721ad73f1ef8202752b624e96951d","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-12-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-07","outcome":"passed","proposal_text":"Ratification of the advisory vote on the named executive officers’ compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,509,073","subject":null,"votes_abstain":"6,806","votes_against":"94,156","votes_for":"5,964,147","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification of the advisory vote on the named executive officers’ compensation at the 2023-12-07 meeting.","evidence_excerpt":"Proposal No. 2 : The Company’s stockholders ratified the advisory vote on the named executive officers’ compensation.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044431","anchor_url":"https://secwatch.observer/filing/0001493152-23-044431#claim-653a70d1804721ad73f1ef8202752b624e96951d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223044431/0001493152-23-044431-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8a7c9a1661b4b0eeb5114bfa7984852946a81750","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-12-11T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-12-07","outcome":"passed","proposal_text":"Election of six nominees to the Board of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"4,509,073","subject":"Zackary Irani","votes_abstain":null,"votes_against":null,"votes_for":"5,973,554","votes_withheld":"91,555"},{"broker_non_votes":"4,509,073","subject":"Allen Barbieri","votes_abstain":null,"votes_against":null,"votes_for":"5,996,037","votes_withheld":"69,072"},{"broker_non_votes":"4,509,073","subject":"Jane Emerson, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"5,908,641","votes_withheld":"156,468"},{"broker_non_votes":"4,509,073","subject":"Catherine Coste","votes_abstain":null,"votes_against":null,"votes_for":"6,012,854","votes_withheld":"52,255"},{"broker_non_votes":"4,509,073","subject":"David Moatazedi","votes_abstain":null,"votes_against":null,"votes_for":"5,994,765","votes_withheld":"70,344"},{"broker_non_votes":"4,509,073","subject":"Jack Kenny","votes_abstain":null,"votes_against":null,"votes_for":"5,994,647","votes_withheld":"70,462"}]},"claim":"BIOMERICA INC shareholders approved Election of six nominees to the Board of Directors at the 2023-12-07 meeting.","evidence_excerpt":"Proposal No. 1 : The Company’s stockholders elected each of the six nominees named below to serve on the Company’s Board of Directors until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-044431","anchor_url":"https://secwatch.observer/filing/0001493152-23-044431#claim-8a7c9a1661b4b0eeb5114bfa7984852946a81750","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223044431/0001493152-23-044431-index.htm"},{"fact_type":"executive_change","fact_key":"2f827cce0c","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-08-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-08-25","interim":false,"role":"Independent Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jack Kenny was appointed as Independent Director at BIOMERICA INC.","evidence_excerpt":"Effective August 25, 2023, the board of directors (the “Board”) of Biomerica, Inc. (the “Company”) expanded the size of the Board by one member and elected and appointed Mr. Jack Kenny to serve as an independent member of the Board effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-030303","anchor_url":"https://secwatch.observer/filing/0001493152-23-030303#claim-2f827cce0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000149315223030303/0001493152-23-030303-index.htm"},{"fact_type":"governance_change","fact_key":"ec6ab2058883db384fb6a8d4f3750f8379a0eb6e","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-07-26T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-07-24","item_codes_triggered":["5.03"],"summary_text":"Amended voting standard for stockholder matters (excluding director elections) from majority of stockholders present and entitled to vote to majority of stockholders present and entitled to vote on the subject matter, to limit effect of broker non-votes."},"claim":"BIOMERICA INC: Amended voting standard for stockholder matters (excluding director elections) from majority of stockholders present and entitled to vote to majority of stockholders present and entitled to vote on the subject matter, to limit effect of broker non-votes (effective 2023-07-24).","evidence_excerpt":"On July 24, 2023, the Board of Directors (the “Board”) of Biomerica Inc. (the “Company”) approved the amendment and restatement of the Company’s Amended and Restated Bylaws (the “Bylaws,” and as so amended and restated, the “Amended and Restated Bylaws”), effective July 24, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-23-000117","anchor_url":"https://secwatch.observer/filing/0001513162-23-000117#claim-ec6ab2058883db384fb6a8d4f3750f8379a0eb6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316223000117/0001513162-23-000117-index.htm"},{"fact_type":"material_agreement","fact_key":"06b6e04d90d4cfc8e4fc720186e482ef2587747c","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-03-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Craig-Hallum Capital Group LLC","effective_date":"2023-03-03","item_codes_triggered":["1.01"],"value_text":"3,333,333 shares of Common Stock at $2.40 per share"},"claim":"BIOMERICA INC entered into Underwriting Agreement with Craig-Hallum Capital Group LLC valued at 3,333,333 shares of Common Stock at $2.40 per share (effective 2023-03-03).","evidence_excerpt":"On March 3, 2023, Biomerica, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Craig-Hallum Capital Group LLC (the “Underwriter”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of an aggregate of 3,333,333 shares of the Company’s common stock, par value $0.08 per share (“Common Stock”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-23-000034","anchor_url":"https://secwatch.observer/filing/0001513162-23-000034#claim-06b6e04d90d4cfc8e4fc720186e482ef2587747c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316223000034/0001513162-23-000034-index.htm"},{"fact_type":"executive_change","fact_key":"b6f05ee936","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2023-03-01","interim":false,"role":"interim Chief Financial Officer","role_category":"cfo","successor_name":"Gary Lu","successor_named":true},"claim":"Steve Sloan departed as interim Chief Financial Officer at BIOMERICA INC.","evidence_excerpt":"In connection with Mr. Lu’s appointment as Chief Financial Officer, Steve Sloan, the Company’s former Chief Financial Officer and current interim Chief Financial Officer, stepped down as interim Chief Financial Officer, effective as of March 1, 2023.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001513162-23-000023","anchor_url":"https://secwatch.observer/filing/0001513162-23-000023#claim-b6f05ee936","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316223000023/0001513162-23-000023-index.htm"},{"fact_type":"executive_change","fact_key":"6323505851","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2023-03-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Gary Lu was appointed as Chief Financial Officer at BIOMERICA INC.","evidence_excerpt":"Effective March 1, 2023, the Board of Directors of Biomerica, Inc. (the “Company”) appointed Gary Lu as its Chief Financial Officer, principal financial officer and principal accounting officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001513162-23-000023","anchor_url":"https://secwatch.observer/filing/0001513162-23-000023#claim-6323505851","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316223000023/0001513162-23-000023-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a7c0cea4e42133d5b6165533295f808641f05d93","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"failed","proposal_text":"Ratification and approval of the Company's 2022 Stock Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,475,235","subject":null,"votes_abstain":"28,371","votes_against":"2,227,813","votes_for":"2,395,243","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders rejected Ratification and approval of the Company's 2022 Stock Incentive Plan at the 2022-12-07 meeting.","evidence_excerpt":"Proposal No. 5 :  The Company’s stockholders did not ratify and approve the Company’s 2022 Stock Incentive Plan. Votes For Votes Against Votes Abstaining Broker Non-Votes 2,395,243 2,227,813 28,371 2,475,235","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-22-000153","anchor_url":"https://secwatch.observer/filing/0001513162-22-000153#claim-a7c0cea4e42133d5b6165533295f808641f05d93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000153/0001513162-22-000153-index.htm"},{"fact_type":"shareholder_vote","fact_key":"40c7b02fb360cfea2e93d0316a4637e2edb57301","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Ratification of appointment of Haskell & White LLP as independent public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"--","subject":null,"votes_abstain":"8,439","votes_against":"70,909","votes_for":"7,047,314","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification of appointment of Haskell & White LLP as independent public accounting firm at the 2022-12-07 meeting.","evidence_excerpt":"Proposal No. 4 :  The Company’s stockholders ratified the appointment of Haskell & White LLP as the Company’s independent public accounting firm for the fiscal year ending May 31, 2023. Votes For Votes Against Votes Abstaining Broker Non-Votes 7,047,314 70,909 8,439 --","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-22-000153","anchor_url":"https://secwatch.observer/filing/0001513162-22-000153#claim-40c7b02fb360cfea2e93d0316a4637e2edb57301","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000153/0001513162-22-000153-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ce6b0ca485ddff8703103146bcfaffafc0e3d3b9","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Frequency of future advisory votes on executive compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"2,623,322","subject":null,"votes_abstain":"94,240","votes_against":"1,079,888","votes_for":"3,466,478","votes_withheld":"10,821"}]},"claim":"BIOMERICA INC shareholders approved Frequency of future advisory votes on executive compensation at the 2022-12-07 meeting.","evidence_excerpt":"Proposal No. 3 :  A majority of the Company’s stockholders voted on the option of every one year as the frequency of future advisory votes on executive compensation. Every one year Every two years Every three years Abstain Broker Non-Votes 3,466,478 1,079,888 10,821 94,240 2,623,322","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-22-000153","anchor_url":"https://secwatch.observer/filing/0001513162-22-000153#claim-ce6b0ca485ddff8703103146bcfaffafc0e3d3b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000153/0001513162-22-000153-index.htm"},{"fact_type":"shareholder_vote","fact_key":"35d9244cdd34af2ef7044bd53addf9f288e568a8","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Ratification of advisory vote on named executive officers' compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,475,235","subject":null,"votes_abstain":"36,548","votes_against":"44,365","votes_for":"4,570,514","votes_withheld":null}]},"claim":"BIOMERICA INC shareholders approved Ratification of advisory vote on named executive officers' compensation at the 2022-12-07 meeting.","evidence_excerpt":"Proposal No. 2 :  The Company’s stockholders ratified the advisory vote on the named executive officers’ compensation. Votes For Votes Against Votes Abstaining Broker Non-Votes 4,570,514 44,365 36,548 2,475,235","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-22-000153","anchor_url":"https://secwatch.observer/filing/0001513162-22-000153#claim-35d9244cdd34af2ef7044bd53addf9f288e568a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000153/0001513162-22-000153-index.htm"},{"fact_type":"shareholder_vote","fact_key":"452dd1f5e5d9779a3ef62fe38f2b497c1c4ee7a4","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,475,235","subject":"Zackary Irani","votes_abstain":null,"votes_against":null,"votes_for":"4,584,648","votes_withheld":"66,779"},{"broker_non_votes":"2,475,235","subject":"Allen Barbieri","votes_abstain":null,"votes_against":null,"votes_for":"4,571,211","votes_withheld":"80,216"},{"broker_non_votes":"2,475,235","subject":"Catherine Coste","votes_abstain":null,"votes_against":null,"votes_for":"3,977,463","votes_withheld":"673,964"},{"broker_non_votes":"2,475,235","subject":"Jane Emerson, M.D., Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,041,002","votes_withheld":"1,610,425"},{"broker_non_votes":"2,475,235","subject":"David Moatazedi","votes_abstain":null,"votes_against":null,"votes_for":"4,620,764","votes_withheld":"30,663"}]},"claim":"BIOMERICA INC shareholders approved Election of Directors at the 2022-12-07 meeting.","evidence_excerpt":"Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal. Nominee Votes For Votes Withheld Broker Non-votes Zackary Irani 4,584,648 66,779 2,475,235 Allen Barbieri 4,571,211 80,216 2,475,235 Catherine Coste 3,977,463 673,964 2,475,235 Jane Emerson, M.D., Ph.D. 3,041,002 1,610,425 2,475,235 David Moatazedi 4,620,764 30,663 2,475,235","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001513162-22-000153","anchor_url":"https://secwatch.observer/filing/0001513162-22-000153#claim-452dd1f5e5d9779a3ef62fe38f2b497c1c4ee7a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000153/0001513162-22-000153-index.htm"},{"fact_type":"executive_change","fact_key":"2dd174d3cb","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-16T23:59:59+00:00","payload":{"action":"stepping down","action_category":"role_change","departure_tone":"routine","effective_date":null,"interim":true,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Steve Sloan changed role as Chief Financial Officer at BIOMERICA INC.","evidence_excerpt":"On December 12, 2022, Steve Sloan notified Biomerica Inc. (the “Company”) that he will be stepping down from his position as Chief Financial Officer (“CFO”) of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000147","anchor_url":"https://secwatch.observer/filing/0001513162-22-000147#claim-2dd174d3cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000147/0001513162-22-000147-index.htm"},{"fact_type":"shareholder_vote","fact_key":"6e9606fc0804e6756bcf8488e805d3e5d894a71c","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Ratification and approval of the 2022 Stock Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"2,475,235","subject":null,"votes_abstain":"28,371","votes_against":"2,227,813","votes_for":"2,395,243","votes_withheld":"0"}]},"claim":"BIOMERICA INC shareholders approved Ratification and approval of the 2022 Stock Incentive Plan at the 2022-12-07 meeting.","evidence_excerpt":"Item 5.07  Submission of Matters to a Vote of Security Holders. Biomerica, Inc. (the “Company”) held its 2022 annual meeting (the “2022 Annual Meeting”) of stockholders of the Company on December 7, 2022, at its corporate headquarter in Irvine, California. As of October 14, 2022, the record date for the 2022 Annual Meeting, the Company had 13,474,338 shares of its common stock outstanding and entitled to vote, of which 7,126,662 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2022 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2022 Annual Meeting. Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000140","anchor_url":"https://secwatch.observer/filing/0001513162-22-000140#claim-6e9606fc0804e6756bcf8488e805d3e5d894a71c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000140/0001513162-22-000140-index.htm"},{"fact_type":"shareholder_vote","fact_key":"8af6cf63e47a5058984beaabaff086c1847b9bb2","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Ratification of appointment of Haskell & White LLP as independent auditor","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"8,439","votes_against":"70,909","votes_for":"7,047,314","votes_withheld":"0"}]},"claim":"BIOMERICA INC shareholders approved Ratification of appointment of Haskell & White LLP as independent auditor at the 2022-12-07 meeting.","evidence_excerpt":"Item 5.07  Submission of Matters to a Vote of Security Holders. Biomerica, Inc. (the “Company”) held its 2022 annual meeting (the “2022 Annual Meeting”) of stockholders of the Company on December 7, 2022, at its corporate headquarter in Irvine, California. As of October 14, 2022, the record date for the 2022 Annual Meeting, the Company had 13,474,338 shares of its common stock outstanding and entitled to vote, of which 7,126,662 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2022 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2022 Annual Meeting. Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000140","anchor_url":"https://secwatch.observer/filing/0001513162-22-000140#claim-8af6cf63e47a5058984beaabaff086c1847b9bb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000140/0001513162-22-000140-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b631e3c06f95bac9f6574422bffe62273b6f5ab9","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Frequency of future advisory votes on executive compensation (every one year)","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"2,623,322","subject":null,"votes_abstain":"94,240","votes_against":"1,090,909","votes_for":"3,466,478","votes_withheld":"0"}]},"claim":"BIOMERICA INC shareholders approved Frequency of future advisory votes on executive compensation (every one year) at the 2022-12-07 meeting.","evidence_excerpt":"Item 5.07  Submission of Matters to a Vote of Security Holders. Biomerica, Inc. (the “Company”) held its 2022 annual meeting (the “2022 Annual Meeting”) of stockholders of the Company on December 7, 2022, at its corporate headquarter in Irvine, California. As of October 14, 2022, the record date for the 2022 Annual Meeting, the Company had 13,474,338 shares of its common stock outstanding and entitled to vote, of which 7,126,662 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2022 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2022 Annual Meeting. Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000140","anchor_url":"https://secwatch.observer/filing/0001513162-22-000140#claim-b631e3c06f95bac9f6574422bffe62273b6f5ab9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000140/0001513162-22-000140-index.htm"},{"fact_type":"shareholder_vote","fact_key":"459aa535e66abd6b61d2d9e974e9a19100d8a6fa","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Advisory vote on named executive officers' compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,475,235","subject":null,"votes_abstain":"36,548","votes_against":"44,365","votes_for":"4,570,514","votes_withheld":"0"}]},"claim":"BIOMERICA INC shareholders approved Advisory vote on named executive officers' compensation at the 2022-12-07 meeting.","evidence_excerpt":"Item 5.07  Submission of Matters to a Vote of Security Holders. Biomerica, Inc. (the “Company”) held its 2022 annual meeting (the “2022 Annual Meeting”) of stockholders of the Company on December 7, 2022, at its corporate headquarter in Irvine, California. As of October 14, 2022, the record date for the 2022 Annual Meeting, the Company had 13,474,338 shares of its common stock outstanding and entitled to vote, of which 7,126,662 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2022 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2022 Annual Meeting. Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000140","anchor_url":"https://secwatch.observer/filing/0001513162-22-000140#claim-459aa535e66abd6b61d2d9e974e9a19100d8a6fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000140/0001513162-22-000140-index.htm"},{"fact_type":"shareholder_vote","fact_key":"77b4ea910b24e827143df5421d2a68ae673145d6","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2022-12-07","outcome":"passed","proposal_text":"Election of five nominees to the Board of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,475,235","subject":"Zackary Irani","votes_abstain":"0","votes_against":"0","votes_for":"4,584,648","votes_withheld":"66,779"},{"broker_non_votes":"2,475,235","subject":"Allen Barbieri","votes_abstain":"0","votes_against":"0","votes_for":"4,571,211","votes_withheld":"80,216"},{"broker_non_votes":"2,475,235","subject":"Catherine Coste","votes_abstain":"0","votes_against":"0","votes_for":"3,977,463","votes_withheld":"673,964"},{"broker_non_votes":"2,475,235","subject":"Jane Emerson, M.D., Ph.D.","votes_abstain":"0","votes_against":"0","votes_for":"3,041,002","votes_withheld":"1,610,425"},{"broker_non_votes":"2,475,235","subject":"David Moatazedi","votes_abstain":"0","votes_against":"0","votes_for":"4,620,764","votes_withheld":"30,663"}]},"claim":"BIOMERICA INC shareholders approved Election of five nominees to the Board of Directors at the 2022-12-07 meeting.","evidence_excerpt":"Item 5.07  Submission of Matters to a Vote of Security Holders. Biomerica, Inc. (the “Company”) held its 2022 annual meeting (the “2022 Annual Meeting”) of stockholders of the Company on December 7, 2022, at its corporate headquarter in Irvine, California. As of October 14, 2022, the record date for the 2022 Annual Meeting, the Company had 13,474,338 shares of its common stock outstanding and entitled to vote, of which 7,126,662 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote at the 2022 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2022 Annual Meeting. Proposal No. 1 :  The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors until t he next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000140","anchor_url":"https://secwatch.observer/filing/0001513162-22-000140#claim-77b4ea910b24e827143df5421d2a68ae673145d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000140/0001513162-22-000140-index.htm"},{"fact_type":"executive_change","fact_key":"40bb060dbf","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-07","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Moatazedi was elected as member of the Board of Directors at BIOMERICA INC.","evidence_excerpt":"At the Annual Shareholder Meeting, shareholders elected Mr. David Moatazedi to fill the seat vacated by Mr. Sirgo.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000139","anchor_url":"https://secwatch.observer/filing/0001513162-22-000139#claim-40bb060dbf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000139/0001513162-22-000139-index.htm"},{"fact_type":"executive_change","fact_key":"599ea43be5","cik":73290,"ticker":"BMRA","company_name":"BIOMERICA INC","filed_at":"2022-12-09T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2022-12-07","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":"David Moatazedi","successor_named":true},"claim":"Mark Sirgo departed as member of the Board of Directors at BIOMERICA INC.","evidence_excerpt":"On December 7, 2022, at the Company’s Annual Shareholder Meeting, Mr. Mark Sirgo stepped down as a member of the Board of Directors of Biomerica.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001513162-22-000139","anchor_url":"https://secwatch.observer/filing/0001513162-22-000139#claim-599ea43be5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/73290/000151316222000139/0001513162-22-000139-index.htm"}]}